Trials / Recruiting
RecruitingNCT07093580
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
Phase 1 Study of a Long-acting Injectable S-892216 in Healthy Adult Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- Sponsor
- Shionogi · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-892216-LAI | S-892216-LAI injection will be administered per schedule specified in the arm description. |
| DRUG | Placebo | Physiological saline will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2025-07-29
- Primary completion
- 2027-05-26
- Completion
- 2027-05-26
- First posted
- 2025-07-30
- Last updated
- 2025-08-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07093580. Inclusion in this directory is not an endorsement.